ESG Tracker
  • Companies
  • Rankings
  • Portfolios
  • My Portfolios
  • Log In Log Out
  • Contact

← Back to search

ARROWHEAD PHARMACEUTICALS, INC.

ARWR · NASDAQ

Pharmaceutical Preparation Manufacturing · US

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

Market Data

Price $55.05 +0.04 (+0.07%)
Market Cap$7.71B
P/E Ratio38.11
EPS$—
52W High$76.76
52W Low$9.57
Beta1.30

Data from Finnhub · Updated Mar 15, 2026

Products and Services
  • Company Search
  • Rankings
  • Portfolios
About ESG Tracker
  • FAQ
Legal & Security
  • Disclosures
  • Privacy Policy
Contact
  • Contact Us
ESG Tracker

ESG Tracker is for informational purposes only and does not constitute investment advice. The operator of this site is not a registered investment advisor. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.

Public ESG data sourced from Public Company ESG Ratings Dataset by esgcompare.org, licensed under CC BY-NC-SA 4.0. This site is non-commercial and for informational purposes only.